The week in review

Big news in the diabetes and weight loss world this week, with a crackdown on the compounding of Ozempic and Mounjaro Compounding pharmacies are set to be prohibited from producing replicas of Ozempic (semaglutide) and Mounjaro (tirazapetide) following reports of severe adverse events after taking compounded versions of the drugs. Reactions were mixed, with the

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous Covid: Has it really been so long?
Next Let pharmacists say no to 60-day scripts: CAPS